In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Bag-mask ventilation fails to improve on endotracheal intubation in cardiac arrest (CAAM)

Barcelona, Spain – 28 Aug 2017: Bag-mask ventilation fails to improve on endotracheal intubation in out-of-hospital cardiac arrest patients, according to late-breaking results from the CAAM trial presented today in a Hot Line LBCT Session at ESC Congress. (1)

“Sudden cardiac arrest is the main cause of death worldwide in previously healthy people,” said principal investigator Prof Frederic Adnet, an emergency physician at Avicenne Hospital in Bobigny, France. “Each year it causes 300 000 deaths in the US and more than 200 000 in Europe. Less than 10% of patients survive out-of-hospital cardiac arrest.”

Airway management with endotracheal intubation (ETI; figure 1) has been the standard of care in cardiopulmonary resuscitation of out-of-hospital cardiac arrest victims. But its effectiveness has been challenged by retrospective studies from international registries which suggested that survival is much lower when ETI is performed during resuscitation. The studies have proposed that bag-mask ventilation (BMV; figure 2) is safer and more effective.

The CAAM trial was a prospective, randomised, controlled, multicentre trial which compared the impact of airway management with BMV versus ETI on survival with healthy brain function in out-of-hospital cardiac arrest patients.

The study included 2 043 out-of-hospital cardiac arrest patients from 15 centres in France and five in Belgium. Patients were randomised to receive BMV or ETI during cardiopulmonary resuscitation. The primary endpoint was survival with good neurological function, defined as Glasgow-Pittsburgh Cerebral Performance Categories (CPC) of 2 or less, at 28 days.

The investigators found the same rate of survival with good neurological outcome at day 28 in the two groups (4.2% with BMV versus 4.3% with ETI). However, the BMV technique failed in 6.7% of patients compared to 2.1% with ETI. There was a much greater incidence of regurgitation/aspiration with BMV (15.2%) compared to ETI (7.5%).

Prof Adnet said: “Bag-mask ventilation did not appear to be without danger in our trial. We were surprised by the much higher incidence of failure of the BMV technique compared with ETI. The higher incidence of regurgitation/aspiration in the BMV group confirms previous studies linking BMV with risks for the patient.”

He concluded: “BMV appears less safe than ETI as a means of ventilation during cardiopulmonary resuscitation in out-of-hospital cardiac arrest. Thus, we cannot recommend BMV as the standard method to ventilate out-of-hospital cardiac arrest patients during cardiopulmonary resuscitation.”

Figure 1: Endotracheal intubation (ETI)

 Hot Line 3 - CAAM (1).JPG









Figure 2: Bag-mask ventilation (BMV)

Hot Line 3 - CAAM (2).JPG









Notes to editor

Sources of funding: This trial was supported by the 2013 Hospital Programme for Clinical Research of the French Ministry of Health and by the Research Delegation of the Assistance Publique – Hopitaux de Paris.

Disclosures: None.

References and notes:
(1) The study “AIRWAY MANAGEMENT DURING CARDIOPULMONARY RESUSCITATION: Tracheal intubation versus bag valve mask ventilation” will be presented during:
• The press conference Hot Line: Late Breaking Clinical Trials 3 on Monday 28 August from 08:00 to 09:00.
• The session Hot Line: Late Breaking Clinical Trials 3 on Monday 28 August from 14:00 to 15:30 in Barcelona – Main Auditorium.

ESC Press Office
For more information, please contact the ESC Press Office:
For press enquiries, independent comment on-site, please contact, the Media & Press Coordinator Jacques Olivier COSTA: +34 666 509 856
The press conference timetable is available here.

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.  

About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2017
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 takes place 26 to 30 August at the Fira Gran Via in Barcelona, Spain. The scientific programme is here. More information is available from the ESC Press Office at

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2017. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.